Androgen Receptor Signaling Inhibitors for Metastatic Hormone Sensitive Prostate Cancer in Asians: Indirect Comparison.

ABSTRACT:

Background

Androgen receptor signaling inhibitors (ARSI) combined with androgen deprivation therapy (ADT) have demonstrated significant survival benefits in metastatic hormone-sensitive prostate cancer (mHSPC) in several clinical trials. However, data specifically in Asian patients remain limited, with individual subgroup analyses showing trends that did not reach statistical significance. We conducted a pooled analysis to provide additional evidence regarding the efficacy of ARSI plus ADT in Asian patients with mHSPC.

Methods

We systematically identified clinical trials reporting overall survival (OS) outcomes for ARSI-based doublet therapy in Asian patients with mHSPC. Individual patient data (IPD) were reconstructed from published Kaplan-Meier curves. Data sources include

SUBMITTER: Chen W 

PROVIDER: S-EPMC12908864 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature